Your search history is turned on.
Date: September 2, 2023 Jurisdictions: All jurisdictions
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Evan Levine, Chief Executive Officer of PsyBio Therapeutics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of PsyBio Therapeutics Corp. (the issuer) for the interim period ended June 30,...
PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale PsyBio continues to develop psycho-targeted, biosynthesized tryptamines and with this authorization becomes the first biotechnology company to obtain government sanctioned, formal, written authorization to manufacture biosynthetic tryptamines including PsyBio-11142 at scale Oxford, Ohio and Denver, Colorado--(New...
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Noah Davis, Chief Financial Officer of PsyBio Therapeutics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of PsyBio Therapeutics Corp. (the issuer) for the interim period ended June 30, ...
Microsoft Word - 2023-06-30- PSYB - MD&A V1 PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) Managements Discussion and Analysis of Financial Condition and Operating Performance For the six months ended June 30, 2023 and 2022 Date: August 31, 2023 2 PsyBio Therapeutics Corp. (formerly Leo Acquisitio...
Microsoft Word - Q2 2023 draft 1.0 financials PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) Condensed Consolidated Interim Financial Statements For the six months ended June 30, 2023 and 2022 (Stated in US Dollars) (Unaudited) PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) C...
Date: January 13, 2023 Jurisdictions: All jurisdictions
PsyBio Announces Closing of Second Tranche of Private Placement Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 13, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neuro...
Date: January 10, 2023 Jurisdictions: All jurisdictions
PsyBio Announces Appointment of Ian Wisenberg to Board of Directors Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 10, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused on the discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and...
Date: January 6, 2023 Jurisdictions: All jurisdictions
PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 5, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property drive...
Date: December 8, 2022 Jurisdictions: All jurisdictions
Microsoft Word - PsyBio - Press Release re Protect the Toads and Provisional Patent Filings (2022)(51394115.3) PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT PsyBio continues to demonstrate...
Date: December 6, 2022 Jurisdictions: All jurisdictions
Microsoft Word - PsyBio - [Draft] Press Release - Four Additional PCT Filings (December 6, 2022)(51356311.2) PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio PsyBio continues to increase its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly comm...